Page 17 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

References 1
1. Scrip’s Cancer Chemotherapy Report. Scrip world pharmaceutical news London: PJB Publications
Ltd. 2002.
2. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44.
3. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,
UFT, S-1): a review. Oncologist. 2002;7(4):288-323.
4. Silvestris N, Maiello E, De Vita F, et al. Update on capecitabine alone and in combination regimens
in colorectal cancer patients. Cancer Treat Rev. 2010;36 Suppl 3:S46-55.
5. Bosset JF, Pavy JJ, Hamers HP, et al. Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. Eur J Cancer. 1993;29a(10):1406-1410.
6. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of
tumour-inhibitory compounds. Nature. 1957;179(4561):663-666.
7. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies.
Nat Rev Cancer. 2003;3(5):330-338.
8. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following
oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291-
297.
9. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine,
a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol.
1998;55(7):1091-1097.
10. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine,
which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver
and cancer tissue. Eur J Cancer. 1998;34(8):1274-1281.
11. Rosmarin D, Palles C, Pagnamenta A, et al. A candidate gene study of capecitabine-related toxicity
in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather
than TYMS. Gut. 2015;64(1):111-120.
12. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to
fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of
CALGB 89803. J Clin Oncol. 2007;25(23):3456-3461.
13. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and
2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-
analysis. Pharmacogenomics. 2013;14(11):1255-1272.
14. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215-
237.
15. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of
5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203-2206.
16. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal
Cancer. 2010;9(4):224-228.
17. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human
tissues. Cancer Res. 1985;45(11 Pt 1):5405-5412
18. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil
General introduction
15